Metglip DS is used to treat Type 2 Diabetes Mellitus
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
It is unsafe to consume alcohol while taking Metglip DS. Alcohol can lower blood sugar levels, leading to potential dangers. Additionally, alcohol can increase the risk of a serious condition called lactic acidosis.
Metglip DS should not be used during pregnancy as it may harm the unborn baby. Insulin is generally preferred for managing diabetes during pregnancy. Always consult your doctor before taking any medication during pregnancy.
Avoid using Metglip DS while breastfeeding as there is limited information available about its safety for lactating women. Consult your doctor before using any medication while breastfeeding.
Metglip DS can cause low blood sugar levels (hypoglycemia), which may impair your ability to drive safely. It's important to keep sources of sugar, juice, or a chocolate bar in your car in case you experience hypoglycemic symptoms such as dizziness, drowsiness, visual disturbances, or sweating while driving. If these symptoms occur, stop driving immediately and consume sugar or juice. Do not use sugar-free products during such episodes.
Let your doctor know if you have any history of kidney diseases when you are prescribed Metglip DS.
Let your doctor know if you have any history of liver diseases or hepatic impairment when you are prescribed Metglip DS.
Type 2 Diabetes Mellitus
Metglip DS works by the combined action of Glipizide and Metformin. Metformin works by decreasing the amount of glucose absorbed from the intestine, lowering the amount of sugar created by the liver, and facilitating the entry of sugar into the cells. Glipizide works by stimulating the release of insulin from your pancreas, thus reducing blood sugar.
Common side effects of Glipizide and Metformin may include hypoglycemia, diarrhea, nausea/vomiting, abdominal pain, headache, and musculoskeletal pain.
Glipizide & Metformin are prescribed to improve glycemic control in patients with type 2 diabetes who cannot effectively manage their hyperglycemia through diet and exercise alone. It is also used as a second-line therapy in individuals with type 2 diabetes when initial treatment with either a Sulfonylurea or Metformin, along with lifestyle modifications, does not achieve adequate glycemic control.
Metformin: This biguanide antihyperglycemic drug enhances glucose tolerance in type 2 diabetic patients by reducing both fasting and post-meal blood glucose levels. It improves insulin sensitivity by increasing peripheral glucose uptake and utilization, decreases glucose production in the liver, and reduces intestinal glucose absorption. Unlike sulfonylureas, Metformin does not cause hypoglycemia or excessive insulin secretion.
Glipizide: This sulfonylurea medication stimulates insulin production from the pancreas, primarily by enhancing the function of beta cells in the pancreatic islets. The mechanism of action of oral sulfonylureas may include extrapancreatic effects.
Glipizide & Metformin should be taken once or twice daily with meals and should be initiated at a low dose, followed by gradual dose escalation.
Initial Therapy: The recommended starting dose is 250 mg/2.5 mg once a day with a meal.
Second-Line Therapy: The recommended starting dose is 500 mg/2.5 mg or 500 mg/5 mg twice daily with morning and evening meals. The maximum daily dose recommended is 2000 mg Metformin/20 mg Glipizide.
The use of angiotensin-II receptor antagonists during pregnancy should be avoided unless absolutely necessary. These medications have been associated with issues related to blood pressure management, renal function in newborns, skull abnormalities, and oligohydramnios. There is limited information on the use of angiotensin-II receptor antagonists during breastfeeding, and they are not recommended while nursing.
Metformin is primarily eliminated through the kidneys, and the risk of Metformin accumulation and lactic acidosis increases as renal function declines. Patients with serum creatinine levels above the upper limit of normal should not receive Metformin. Metformin dosing should be carefully adjusted in elderly individuals with advanced age-related renal function decline. Metformin therapy should be temporarily discontinued before surgery and should not be resumed until the patient's oral intake is restored, and normal renal function is confirmed.
Store at temperatures not exceeding 30°C (86°F) and keep out of reach of children.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.